EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predictive immunoinformatics reveal promising safety and anti-onchocerciasis protective immune response profiles to vaccine candidates (Ov-RAL-2 and Ov-103) in anticipation of phase I clinical trials

Derrick Neba Nebangwa iD, Robert Adamu Shey iD, Daniel Madulu Shadrack, Cabirou Mounchili Shintouo, Ntang Emmaculate Yaah, Bernis Neneyoh Yengo, Mary Teke Efeti, Ketura Yaje Gwei, Darling Bih Aubierge Fomekong, Gordon Takop Nchanji, Arnaud Azonpi Lemoge, Fidele Ntie-Kang iD und 1 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0312315 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Derrick Neba Nebangwa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Faculty of Science, University of Buea, Buea, Cameroon. Hauptthemen laut MEDLINE: Onchocerciasis, Vaccines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Onchocerciasis (river blindness) is a debilitating tropical disease that causes significant eye and skin damage, afflicting millions worldwide. As global efforts shift from disease management to elimination, vaccines have become crucial supplementary tools. The Onchocerciasis Vaccine for Africa (TOVA) Initiative was established in 2015, to advance at least one vaccine candidate initially targeting onchocerciasis in infants and children below 5 years of age, through Phase I human trials by 2025. Notably, Ov -RAL-2 and Ov -103 antigens have shown great promise during pre-clinical development, however, the overall success rate of vaccine candidates during clinical development remains relatively low due to certain adverse effects and immunogenic limitations. This study, thus, aimed at predicting the safety and immunogenicity of Ov -RAL-2 and Ov -103 potential onchocerciasis vaccine candidates prior to clinical trials. Advanced molecular simulation models and analytical immunoinformatics algorithms were applied to predict potential adverse side effects and efficacy of these antigens in humans. The analyses revealed that both Ov -RAL-2 and Ov -103 demonstrate favourable safety profiles as toxicogenic and allergenic epitopes were found to be absent within each antigen. Also, both antigens were predicted to harbour substantial numbers of a wide range of distinct epitopes (antibodies, cytokines, and T- Cell epitopes) associated with protective immunity against onchocerciasis. In agreement, virtual vaccination simulation forecasted heightened, but sustained levels of primary and secondary protective immune responses to both vaccine candidates over time. Ov -103 was predicted to be non-camouflageable, as it lacked epitopes identical to protein sequences in the human proteome. Indeed, both antigens were able to bind with high affinity and activate the innate immune TLR4 receptor, implying efficient immune recognition. These findings suggest that Ov -RAL-2 and Ov -103 can induce sufficient protective responses through diverse humoral and cellular mechanisms. Overall, our study provides additional layer of evidence for advancing the clinical development of both vaccine candidates against onchocerciasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OnchocerciasisVaccinesHumansComputational BiologyClinical Trials, Phase I as TopicAntigens, HelminthAnimalsOnchocerca volvulusImmunoinformatics

Substanzen

VaccinesAntigens, Helminth

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, Faculty of Science, University of Buea, Buea, Cameroon.
  • Tropical Disease Interventions, Diagnostics, Vaccines and Therapeutics (TroDDIVaT) Initiative, Buea, Cameroon.
  • Department of Chemistry, St. John's University of Tanzania, Dodoma, Tanzania.
  • Department of Microbiology and Immunology, College of Medicine, Drexel University, Philadelphia, Pennsylvania, United States of America.
  • Department of Nursing, Mount Zion Higher Institute, Mankon, Bamenda, Cameroon.
  • Department of Microbiology and Parasitology, Faculty of Science, University of Buea, Buea, Cameroon.

ORCID-Profile: Derrick Neba Nebangwa, Robert Adamu Shey, Fidele Ntie-Kang

Zitieren

APA

Nebangwa, D. N., Shey, R. A., Shadrack, D. M., Shintouo, C. M., Yaah, N. E., Yengo, B. N., Efeti, M. T., Gwei, K. Y., Fomekong, D. B. A., Nchanji, G. T., Lemoge, A. A., Ntie-Kang, F., & Ghogomu, S. M. (2024). Predictive immunoinformatics reveal promising safety and anti-onchocerciasis protective immune response profiles to vaccine candidates (Ov-RAL-2 and Ov-103) in anticipation of phase I clinical trials. PLOS ONE. https://doi.org/10.1371/journal.pone.0312315

Vancouver

Nebangwa DN, Shey RA, Shadrack DM, Shintouo CM, Yaah NE, Yengo BN, et al. Predictive immunoinformatics reveal promising safety and anti-onchocerciasis protective immune response profiles to vaccine candidates (Ov-RAL-2 and Ov-103) in anticipation of phase I clinical trials. PLOS ONE. 2024. doi:10.1371/journal.pone.0312315

BibTeX
@article{Nebangwa2024,
  author = {Nebangwa, Derrick Neba and Shey, Robert Adamu and Shadrack, Daniel Madulu and Shintouo, Cabirou Mounchili and Yaah, Ntang Emmaculate and Yengo, Bernis Neneyoh and Efeti, Mary Teke and Gwei, Ketura Yaje and Fomekong, Darling Bih Aubierge and Nchanji, Gordon Takop and Lemoge, Arnaud Azonpi and Ntie-Kang, Fidele and Ghogomu, Stephen Mbigha},
  title = {Predictive immunoinformatics reveal promising safety and anti-onchocerciasis protective immune response profiles to vaccine candidates (Ov-RAL-2 and Ov-103) in anticipation of phase I clinical trials},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0312315}
}
Kostenlos starten →